<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:43:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10417064" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10417064</identifier>
        <datestamp>2023-08-12</datestamp>
        <setSpec>canmed</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cam46187" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
              <journal-id journal-id-type="publisher-id">CAM4</journal-id>
              <journal-title-group>
                <journal-title>Cancer Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-7634</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10417064</article-id>
              <article-id pub-id-type="pmcid">PMC10417064</article-id>
              <article-id pub-id-type="pmc-uid">10417064</article-id>
              <article-id pub-id-type="pmid">37269192</article-id>
              <article-id pub-id-type="pmid">37269192</article-id>
              <article-id pub-id-type="doi">10.1002/cam4.6187</article-id>
              <article-id pub-id-type="publisher-id">CAM46187</article-id>
              <article-id pub-id-type="other">CAM4-2022-09-4069.R1</article-id>
              <article-categories>
                <subj-group subj-group-type="article-subject-classification">
                  <subject>Cancer Prevention</subject>
                </subj-group>
                <subj-group subj-group-type="article-subject-classification">
                  <subject>Cancer Risk Factors</subject>
                </subj-group>
                <subj-group subj-group-type="article-subject-classification">
                  <subject>Epidemiology and Prevention</subject>
                </subj-group>
                <subj-group subj-group-type="article-subject-classification">
                  <subject>Epidemiology</subject>
                </subj-group>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>RESEARCH ARTICLES</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Cancer Prevention</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer</article-title>
                <alt-title alt-title-type="left-running-head">Cartmel et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cam46187-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Cartmel</surname>
                    <given-names>Brenda</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4748-5143</contrib-id>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam46187-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>brenda.cartmel@yale.edu</email>
                  </address>
                </contrib>
                <contrib id="cam46187-cr-0002" contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Fang‐yong</given-names>
                  </name>
                  <xref rid="cam46187-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0003" contrib-type="author">
                  <name>
                    <surname>Zhou</surname>
                    <given-names>Yang</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam46187-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0004" contrib-type="author">
                  <name>
                    <surname>Gottlieb</surname>
                    <given-names>Linda</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0005" contrib-type="author">
                  <name>
                    <surname>Lu</surname>
                    <given-names>Lingeng</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam46187-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0006" contrib-type="author">
                  <name>
                    <surname>Mszar</surname>
                    <given-names>Reed</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0007" contrib-type="author">
                  <name>
                    <surname>Harrigan</surname>
                    <given-names>Maura</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0008" contrib-type="author">
                  <name>
                    <surname>Ligibel</surname>
                    <given-names>Jennifer A.</given-names>
                  </name>
                  <xref rid="cam46187-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0009" contrib-type="author">
                  <name>
                    <surname>Gogoi</surname>
                    <given-names>Radhika</given-names>
                  </name>
                  <xref rid="cam46187-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="cam46187-curr-0001" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0010" contrib-type="author">
                  <name>
                    <surname>Schwartz</surname>
                    <given-names>Peter E.</given-names>
                  </name>
                  <xref rid="cam46187-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam46187-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0011" contrib-type="author">
                  <name>
                    <surname>Risch</surname>
                    <given-names>Harvey A.</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam46187-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam46187-cr-0012" contrib-type="author">
                  <name>
                    <surname>Irwin</surname>
                    <given-names>Melinda L.</given-names>
                  </name>
                  <xref rid="cam46187-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam46187-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="cam46187-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Chronic Disease Epidemiology</named-content>
                <institution>Yale School of Public Health</institution>
                <named-content content-type="country-part">New Haven</named-content>
                <city>Connecticut</city>
                <country country="US">USA</country>
              </aff>
              <aff id="cam46187-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Yale Cancer Center</institution>
                <named-content content-type="country-part">New Haven</named-content>
                <city>Connecticut</city>
                <country country="US">USA</country>
              </aff>
              <aff id="cam46187-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics</named-content>
                <institution>Yale School of Public Health</institution>
                <named-content content-type="country-part">New Haven</named-content>
                <city>Connecticut</city>
                <country country="US">USA</country>
              </aff>
              <aff id="cam46187-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medical Oncology</named-content>
                <institution>Dana‐Farber Cancer Institute</institution>
                <named-content content-type="country-part">Boston</named-content>
                <city>Massachusetts</city>
                <country country="US">USA</country>
              </aff>
              <aff id="cam46187-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Gynecologic Oncology, Women and Children's Institute</named-content>
                <institution>Geisinger Health System</institution>
                <named-content content-type="country-part">Danville</named-content>
                <city>Pennsylvania</city>
                <country country="US">USA</country>
              </aff>
              <aff id="cam46187-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Section of Medical Oncology, Department of Internal Medicine</named-content>
                <institution>Yale School of Medicine</institution>
                <named-content content-type="country-part">New Haven</named-content>
                <city>Connecticut</city>
                <country country="US">USA</country>
              </aff>
              <aff id="cam46187-curr-0001"><label><sup>7</sup></label>Present address:
<named-content content-type="organisation-division">Department of Obstetrics &amp; Gynecology</named-content><institution>Wayne State University</institution><named-content content-type="country-part">Detroit</named-content><city>Michigan</city><country country="US">USA</country></aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Brenda Cartmel, Yale School of Public Health, 1 Church St, Suite 200, New Haven, CT 06510, USA.<break/>
Email: <email>brenda.cartmel@yale.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>03</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="540">14</issue>
              <issue-id pub-id-type="doi">10.1002/cam4.v12.14</issue-id>
              <fpage>15492</fpage>
              <lpage>15503</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>13</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="received">
                  <day>13</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 Published by John Wiley & Sons Ltd.-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CAM4-12-15492.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="cam46187-sec-0001">
                  <title>Background</title>
                  <p>In randomized trials in women with breast cancer, exercise has been shown to have beneficial effects on cancer‐related circulating biomarkers that may impact survival. Such studies are lacking for ovarian cancer.</p>
                </sec>
                <sec id="cam46187-sec-0002">
                  <title>Methods</title>
                  <p>This secondary analysis of a published randomized controlled trial examined the impact of a 6‐month exercise intervention versus attention‐control on change in prespecified circulating biomarkers (cancer antigen 125 (CA‐125), C‐reactive protein (CRP), insulin‐like growth factor‐1(IGF‐1), insulin and leptin) in a subset of participants who provided a fasting blood draw (<italic toggle="no">N</italic> = 104/144) at enrollment and at 6 months. Change in biomarkers between study arms was compared using a linear mixed effects model analysis. An exploratory analysis of the exercise intervention versus attention‐control on all‐cause mortality included all (<italic toggle="no">N</italic> = 144) participants. All statistical tests were two‐sided.</p>
                </sec>
                <sec id="cam46187-sec-0003">
                  <title>Results</title>
                  <p>Participants included in the biomarker analysis were 57.0 ± 8.8 (mean ± SD) years old and 1.6 ± 0.9 years post‐diagnosis. Adherence to the exercise intervention was 176.4 ± 63.5 min/week. Post intervention IGF‐1 (group difference in change: −14.2 (−26.1 to −2.3) ng/mL (least squared means (95% CI))) and leptin (−8.9 (−16.5 to −1.4) ng/mL) were significantly reduced in the exercise group (<italic toggle="no">N</italic> = 53) compared to those in attention‐control (<italic toggle="no">N</italic> = 51). No group difference in change was seen for CA‐125 (<italic toggle="no">p</italic> = 0.54), CRP (<italic toggle="no">p</italic> = 0.95), or insulin (<italic toggle="no">p</italic> = 0.37). With median follow‐up of 70 months [range 6.6–105.4 months], 50/144 (34.7%) (exercise group; 24/74 (32.4%) versus attention‐control group; 26/70 (37.1%)) participants died with no between group difference in overall survival (<italic toggle="no">p</italic> = 0.99).</p>
                </sec>
                <sec id="cam46187-sec-0004">
                  <title>Conclusions</title>
                  <p>Further studies are needed to determine the clinical significance of exercise‐induced changes in cancer‐related circulating biomarkers in women with ovarian cancer.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="cam46187-kwd-0001">biomarkers</kwd>
                <kwd id="cam46187-kwd-0002">exercise</kwd>
                <kwd id="cam46187-kwd-0003">ovarian neoplasms</kwd>
                <kwd id="cam46187-kwd-0004">survival analysis</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>5R01CA138556</award-id>
                  <award-id>P30 CA016359</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Center for Advancing Translational Sciences
</institution>
                      <institution-id institution-id-type="doi">10.13039/100006108</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UL1TR000142</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <page-count count="12"/>
                <word-count count="6083"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>July 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.2 mode:remove_FC converted:11.08.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="CAM46187-cit-2001"><string-name><surname>Cartmel</surname><given-names>B</given-names></string-name>, <string-name><surname>Li</surname><given-names>F‐y</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, et al. <article-title>Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>:<fpage>15492</fpage>‐<lpage>15503</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.6187</pub-id>
<pub-id pub-id-type="pmid">37269192</pub-id></mixed-citation>
              </p>
              <fn-group id="cam46187-ntgp-0001">
                <fn id="cam46187-note-0001">
                  <p>Clinical trial registration number: <ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">Clinicaltrials.gov</ext-link>: NCT02107066, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02107066" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02107066</ext-link>.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="cam46187-body-0001">
            <sec id="cam46187-sec-0005">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Despite the continuing decline in the incidence of ovarian cancer, it still accounts for 2.5% of all female cancers diagnosed and 5% of all cancer‐related deaths among women in the United States.<xref rid="cam46187-bib-0001" ref-type="bibr"><sup>1</sup></xref> Most cases of ovarian cancer are diagnosed at an advanced stage (Stage III or Stage IV) and while advancements in treatment have resulted in improvements in survival, 5‐year survival remains low, 47% overall with 41% for Stage III, and 20% for Stage IV.<xref rid="cam46187-bib-0001" ref-type="bibr"><sup>1</sup></xref>
</p>
              <p>Numerous observational studies have shown that exercise following diagnosis is associated with a lower mortality risk in breast, colorectal, and prostate cancer survivors<xref rid="cam46187-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cam46187-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cam46187-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam46187-bib-0005" ref-type="bibr"><sup>5</sup></xref> with the limited studies in women with ovarian cancer reporting similar beneficial associations between exercise following diagnosis and mortality.<xref rid="cam46187-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cam46187-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cam46187-bib-0008" ref-type="bibr"><sup>8</sup></xref> However, there is a lack of well‐designed randomized‐controlled trials reporting on the association between exercise following diagnosis of ovarian cancer and survival,<xref rid="cam46187-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="cam46187-bib-0009" ref-type="bibr"><sup>9</sup></xref> and similarly a paucity of published studies exploring potential mechanisms for an effect of exercise after diagnosis on mortality in women with ovarian cancer.</p>
              <p>Several mechanisms have been suggested for the observed association between exercise and reduced mortality risk in patients with cancer including the effect of exercise on (a) body fatness (whole‐body and visceral); (b) adipokines, such as leptin; (c) low‐grade inflammation which can be evaluated via serum C‐reactive protein (CRP); and (d) metabolic dysregulation which can be evaluated for example by serum insulin and insulin‐like growth factor‐1 (IGF‐1).<xref rid="cam46187-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="cam46187-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="cam46187-bib-0012" ref-type="bibr"><sup>12</sup></xref> These mechanisms are supported by numerous studies including several meta‐analyses showing that exercise has a beneficial effect on the pathways and related relevant biomarkers such as leptin, CRP, serum insulin and IGF‐1.<xref rid="cam46187-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cam46187-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cam46187-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="cam46187-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cam46187-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam46187-bib-0018" ref-type="bibr"><sup>18</sup></xref> Based on the above hypothesized mechanisms the prespecified biomarker panel for our study included: CRP, IGF‐1, insulin, and leptin. CA125, an established biomarker of ovarian cancer recurrence, was also included in our prespecified biomarker panel.<xref rid="cam46187-bib-0019" ref-type="bibr"><sup>19</sup></xref>
</p>
              <p>In addition to the above prespecified cancer‐related biomarkers, several exploratory cancer‐related biomarkers were examined in this study. The inflammatory markers interleukin 6 (IL‐6) and tumor necrosis factor alpha (TNFα) were included as inflammation may play a role in cancer recurrence and mortality.<xref rid="cam46187-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="cam46187-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cam46187-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cam46187-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="cam46187-bib-0021" ref-type="bibr"><sup>21</sup></xref> Similarly, vascular endothelium growth factor (VEGF), a regulator of angiogenesis involved in the pathogenesis of ovarian cancer,<xref rid="cam46187-bib-0022" ref-type="bibr"><sup>22</sup></xref> was included. VEGF has been widely studied as a potential prognostic factor for ovarian cancer,<xref rid="cam46187-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="cam46187-bib-0024" ref-type="bibr"><sup>24</sup></xref> with higher levels associated with poorer prognosis. The adipokine, adiponectin, which is responsive to pro‐inflammatory cytokines<xref rid="cam46187-bib-0020" ref-type="bibr"><sup>20</sup></xref> and has an inverse association with leptin was also measured.</p>
              <p>The Women's Activity and Lifestyle Study in Connecticut (WALC) was a 6‐month randomized controlled trial of aerobic exercise versus attention‐control in women with ovarian cancer.<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref> The primary trial results showed that women randomized to exercise experienced statistically significant improvements in health‐related quality of life and cancer‐related fatigue compared to women randomized to attention‐matched control.<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref> In this secondary analysis of a subset of the study population, we report the effect of the exercise intervention on both prespecified (CRP, IGF‐1, insulin, leptin, CA‐125) and exploratory circulating biomarkers (adiponectin, IL‐6, TNFα, VEGF). Due to a lack of existing evidence on the effect of post diagnosis exercise and survival, we also report exploratory outcomes from an unplanned analysis of the exercise intervention effect on ovarian cancer survival.</p>
            </sec>
            <sec sec-type="methods" id="cam46187-sec-0006">
              <label>2</label>
              <title>METHODS</title>
              <sec id="cam46187-sec-0007">
                <label>2.1</label>
                <title>Study population</title>
                <p>Details and primary results of the WALC study have been described elsewhere.<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref> Briefly, 144 women with Stage I–IV ovarian cancer were randomized between May 1, 2010 and March 20, 2014. Eligibility criteria included, English‐speaking individuals between 18 and 75 years of age, diagnosed with ovarian cancer within the past 4 years, and completion of adjuvant therapy (chemotherapy and/or radiation) at least 1 month prior to randomization. Women had to have been exercising less than 90 minutes/week and received physician consent to start an exercise program.</p>
                <p>Eligible women were randomized in a 1:1 ratio to a six‐month exercise program or to an attention‐control group. Randomization was block stratified by disease stage (I and II vs. III and IV) and age (under 55 years vs. 55 years and older). A subset (<italic toggle="yes">n</italic> = 104) of the WALC study population who completed in‐person visits at one of the three enrolling hospitals (Smilow Cancer Hospital at Yale‐New Haven (<italic toggle="yes">n</italic> = 88), Geisinger Health Systems (<italic toggle="yes">n</italic> = 8), and Dana Farber Cancer Center (<italic toggle="yes">n</italic> = 8)) were included in the blood biomarker analysis. Women enrolled at the Smilow Cancer Hospital at Yale‐New Haven, were recruited using the Rapid Case Ascertainment Shared Resource of the Yale Cancer Center that identified women with ovarian cancer from all Connecticut hospitals. The remaining WALC participants (<italic toggle="yes">n</italic> = 40) self‐referred to the study and did not reside near any of the three enrolling hospitals and were therefore unable to complete the blood draw (Figure <xref rid="cam46187-fig-0001" ref-type="fig">1</xref>). All 144 women are included in the survival analysis.</p>
                <fig position="float" fig-type="FIGURE" id="cam46187-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Consort diagram.</p>
                  </caption>
                  <graphic xlink:href="CAM4-12-15492-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
              <sec id="cam46187-sec-0008">
                <label>2.2</label>
                <title>Measures</title>
                <p>Self‐reported socio‐demographic variables were ascertained at baseline. Time since diagnosis, disease stage, family history of ovarian cancer, chemotherapy treatment status, and history of recurrence were obtained via self‐report, with an additional questionnaire on treatment completed by the participants' physicians. Height and weight were measured using standard procedures.<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref> Physical activity levels at baseline and 6 months were assessed using the Modifiable Physical Activity Questionnaire,<xref rid="cam46187-bib-0026" ref-type="bibr"><sup>26</sup></xref> which asked about the frequency and duration and of recreational activities performed during the previous 6 months.</p>
              </sec>
              <sec id="cam46187-sec-0009">
                <label>2.3</label>
                <title>Serum biomarkers</title>
                <p>A 12‐hour fasting blood draw was completed at baseline and at 6 months. Serum samples were kept at −80°C until assayed. Serum concentrations of adiponectin, insulin, and leptin were measured using radioimmunoassay kits (RIA kits from EMD Millipore); cancer antigen 125 (CA‐125), interleukin 6 (IL‐6), insulin‐like growth factor‐1 (IGF‐1) and tumor necrosis factor alpha (TNF‐α) were measured using ELISA kits (R&amp;D Systems, Minneapolis, MN); and vascular endothelial growth factor (VEGF) was analyzed using ELISA kit (Thermofisher Scientific Inc., Waltham, MA); a high sensitivity CRP assay was conducted using an automated chemistry analyzer. None of the laboratory assays were approved for clinical use. Baseline and 6‐month serum samples were assayed at the same time at the end of the study, and samples from participants in both groups were included in each batch of assays. Samples were assayed in duplicate. For all samples, coefficients of variation (CV) were under 10%. Intra‐assay CVs for all assays were less than 5%. Laboratory technicians were blinded to treatment assignment.</p>
              </sec>
              <sec id="cam46187-sec-0010">
                <label>2.4</label>
                <title>Intervention</title>
                <p>The intervention has been described in detail elsewhere.<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref> Briefly, the exercise intervention was a 6‐month moderate‐intensity aerobic home‐based exercise program. A certified cancer exercise trainer phoned women weekly to provide individualized counseling to motivate women to exercise and help facilitate their participation in the recommended 150 min/week of moderate‐intensity aerobic exercise.<xref rid="cam46187-bib-0027" ref-type="bibr"><sup>27</sup></xref> The primary adherence measure of exercise was an activity log maintained by the participant.</p>
                <p>Weekly phone calls were made to those in the attention‐control group during which a WALC staff member discussed topics related to ovarian cancer survivorship.</p>
              </sec>
              <sec id="cam46187-sec-0011">
                <label>2.5</label>
                <title>Mortality data</title>
                <p>A search of the National Death Index and hospital electronic medical records was conducted to determine vital status of study participants (<italic toggle="yes">N</italic> = 144) through December 2018.</p>
              </sec>
              <sec id="cam46187-sec-0012">
                <label>2.6</label>
                <title>Statistical analysis</title>
                <p>Most of the biomarkers analyzed were prespecified (CA‐125, CRP, insulin, IGF‐1, and leptin). Analyses of adiponectin, IL‐6, TNF‐α, and VEGF were unplanned and thus are considered exploratory.</p>
                <p>A mixed model repeated measures analysis<xref rid="cam46187-bib-0028" ref-type="bibr"><sup>28</sup></xref> was used to evaluate baseline to 6‐month differences in serum biomarkers between the groups according to intention‐to‐treat. Baseline measures were included as part of the response profile where the mean scores of the two groups at baseline were constrained to be equal within the regression model. The intervention effect was examined by including a time by group interaction term in the model. Linear contrasts were used to obtain the change scores in each group as well as the group difference. Least‐square mean and standard error, unless otherwise specified, were reported. The maximum likelihood method was used to handle missing data.<xref rid="cam46187-bib-0029" ref-type="bibr"><sup>29</sup></xref> Study site, recurrence before and during the study, chemotherapy at baseline, and two stratification factors for randomization (stage and age) were included as covariates although there was little difference with or without adjustment, therefore, we only present the adjusted results. Women who experienced a recurrence during the study continued with the study to the best of their ability and were included in the analyses. We examined effect modification of exercise on serum biomarkers by recurrence status during the trial.</p>
                <p>Survival analysis is exploratory as an unplanned outcome. Kaplan Meier analysis was performed to compare the overall survival experience between groups. The Cox proportional hazards model was used to evaluate the effect of baseline characteristics, including age at enrollment, BMI, time since diagnosis, family history of ovarian cancer, stage, recurrence prior to enrollment, and employment. Multivariate analysis was performed to control for these potential confounding effects. The supremum test was used to check proportional hazards assumption. A two‐sided 0.05 significance level was applied for all analyses. All analyses were conducted using SAS, Version 9.4 (SAS).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cam46187-sec-0013">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="cam46187-sec-0014">
                <label>3.1</label>
                <title>Blood biomarker analysis</title>
                <p>A total of 104 WALC participants who attended an in‐person clinic visit were included in our analysis of change in biomarkers (53 exercise and 51 attention‐control). A total of 86 (82.7%) (46/53 exercise and 40/51 attention‐control, <italic toggle="yes">p</italic> = 0.26 for comparison of loss to follow‐up) participants had 6‐month blood samples. Primary reasons for loss to follow‐up included being too ill and withdrawing from the study.<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref>
</p>
                <sec id="cam46187-sec-0015">
                  <label>3.1.1</label>
                  <title>Baseline characteristics</title>
                  <p>Participants were 57.0 ± 8.8 (mean ± SD) years of age, 1.6 ± 0.9 years post‐diagnosis, and were participating in 28.3 ± 43.7 minutes/week of moderate‐to‐vigorous intensity exercise at baseline (Table <xref rid="cam46187-tbl-0001" ref-type="table">1</xref>). Most women were diagnosed with Stage III or IV ovarian cancer (51.9%), and 93.3% had received chemotherapy. Baseline characteristics were similar between groups. The baseline characteristics of the subset of 104 participants included in the analysis were similar to the full cohort of 144 participants (Table <xref rid="cam46187-tbl-0001" ref-type="table">1</xref>).</p>
                  <table-wrap position="float" id="cam46187-tbl-0001" content-type="TABLE">
                    <label>TABLE 1</label>
                    <caption>
                      <p>Baseline characteristics by study arm for the biomarker study and the full study.</p>
                    </caption>
                    <table frame="hsides" rules="all">
                      <col align="left" span="1"/>
                      <col align="char" char="(" span="1"/>
                      <col align="char" char="(" span="1"/>
                      <col align="char" char="(" span="1"/>
                      <col align="char" char="(" span="1"/>
                      <thead valign="bottom">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" rowspan="3" valign="bottom" colspan="1"/>
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" colspan="2" valign="bottom" rowspan="1">Biomarker study study arm</th>
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" colspan="2" valign="bottom" rowspan="1">Full study study arm</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Exercise intervention (<italic toggle="yes">N</italic> = 53)<xref rid="cam46187-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Attention‐control (<italic toggle="yes">N</italic> = 51)<xref rid="cam46187-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Exercise intervention (<italic toggle="yes">N</italic> = 74)<xref rid="cam46187-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                          <th align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Attention‐control (<italic toggle="yes">N</italic> = 70)<xref rid="cam46187-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" style="border-right:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Mean(SD) or <italic toggle="yes">n</italic> (%)</th>
                          <th align="left" style="border-right:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Mean(SD) or <italic toggle="yes">n</italic> (%)</th>
                          <th align="left" style="border-right:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Mean(SD) or <italic toggle="yes">n</italic> (%)</th>
                          <th align="left" style="border-right:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Mean(SD) or <italic toggle="yes">n</italic> (%)</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Age (years)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">56.8 (9.4)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">57.2 (8.1)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">57.3 (8.8)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">57.4 (8.5)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Race/ethnicity</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non‐Hispanic white</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">52 (98.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">48 (94.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">72 (97.3%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">65 (92.9%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">1 (1.9%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">3 (5.9%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">2 (2.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">5 (7.1%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Education level</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">GED and some college/associates</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">25 (47.2%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">26 (51.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">39 (52.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">41 (58.6%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">College graduate/advanced degree</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">28 (52.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">25 (49.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">35 (47.3%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">29 (41.4%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Employment status</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unemployed/retired</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">23 (43.4%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">24 (48.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">34 (46.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">35 (50.7%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Employed part time (&lt;35 h/week)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">13 (24.5%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">10 (20.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">22 (29.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">23 (33.3%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Employed full time (&gt;35 h/week)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">17 (32.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">16 (32.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">18 (24.3%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">11 (16.0%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Marital status</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Single</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">3 (5.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">7 (13.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">8 (10.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">7 (10.0%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Divorced, separated, or widowed</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">11 (20.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">6 (11.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">16 (21.6%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">8 (11.4%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Married or living with partner</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">39 (73.6%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">38 (74.5%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">50 (67.6%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">55 (78.6%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Family history of ovarian cancer</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">9 (17.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">5 (10.2%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">11 (14.9%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">7 (10.3%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">44 (83.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">44 (89.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">63 (85.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">61 (89.7%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Stage</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">16 (30.2%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">9 (17.6%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">21 (28.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">13 (18.6%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">II</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">8 (15.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">17 (33.3%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">11 (15.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">19 (27.1%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">21 (39.6%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">16 (31.4%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">31 (42.5%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">27 (38.6%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IV</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">8 (15.1%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">9 (17.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">10 (13.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">11 (15.7%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Chemotherapy prior to enrollment</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">50 (94.3%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">47 (92.2%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">69 (93.2%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">65 (92.9%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">3 (5.7%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">4 (7.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">5 (6.8%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">5 (7.1%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td align="left" style="border-right:solid 1px #000000" colspan="5" valign="top" rowspan="1">Cancer recurrence prior to enrollment</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">9 (17.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">9 (18%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">13 (17.6%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">12 (17.1%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000; padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No/unknown</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">44 (83.0%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">42 (82%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">61 (82.4%)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">58 (82.9%)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Time since diagnosis (years)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">1.7 (0.9)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">1.5 (1.0)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">1.7 (0.9)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">1.7 (1.1)</td>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Body mass index (wt/ht<sup>2</sup> (kg/m<sup>2</sup>))</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">28.7(6.8)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">30.3 (7.1)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">29.0 (7.2)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">29.1 (6.8)</td>
                        </tr>
                        <tr>
                          <td style="border-right:solid 1px #000000" align="left" valign="top" rowspan="1" colspan="1">Physical activity (min/week)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">22 (43.8)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">35.0 (43.0)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">26.0 (44.2)</td>
                          <td style="border-right:solid 1px #000000" align="char" valign="top" rowspan="1" colspan="1">30.8 (38.9)</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot id="cam46187-ntgp-0002">
                      <fn id="cam46187-note-0002">
                        <p><italic toggle="yes">Abbreviations</italic>: kg, kilograms; m, meters; SD, standard deviation; wt, weight.</p>
                      </fn>
                      <fn id="cam46187-note-0003">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
              </sec>
              <sec id="cam46187-sec-0016">
                <label>3.2</label>
                <title>Intervention adherence</title>
                <p>Over the intervention period, women randomized to the exercise arm participated in 176.4 ± 63.5 minutes per week of moderate‐intensity exercise and 73.6% of women met the exercise goal of at least 150 minutes per week. Adherence to 80% of the 25 weekly phone calls was 45/53 (85%) in the intervention arm and 36/51 (71%) in the attention control arm (<italic toggle="yes">p</italic> = 0.08).</p>
              </sec>
              <sec id="cam46187-sec-0017">
                <label>3.3</label>
                <title>Recurrence of ovarian cancer</title>
                <p>During the 6‐month study, of those who had biomarker data available, 26 women (11 (21.2%) exercise group; 15 (31.2%) attention‐control group) experienced a recurrence. Recurrence could not be determined for four women.</p>
              </sec>
              <sec id="cam46187-sec-0018">
                <label>3.4</label>
                <title>Biomarkers</title>
                <p>There were no significant differences between arms for any of the biomarkers at baseline with the exception of the exploratory biomarker TNF‐α with lower levels observed in the exercise arm (<italic toggle="yes">p</italic> = 0.03; Table <xref rid="cam46187-tbl-0002" ref-type="table">2</xref>). Of the prespecified biomarkers, significant between‐group differences were observed for baseline to 6‐month changes for IGF‐1 (<italic toggle="yes">p</italic> = 0.02), and leptin (<italic toggle="yes">p</italic> = 0.02) with reductions in circulating IGF‐1 and leptin in the women randomized to the exercise arm compared to increased levels in both biomarkers in those randomized to attention‐control (Table <xref rid="cam46187-tbl-0003" ref-type="table">3</xref>). No between group effects were observed for CA‐125, CRP or insulin.</p>
                <table-wrap position="float" id="cam46187-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Baseline serum biomarkers.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Biomarker</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Exercise intervention <italic toggle="yes">N</italic> = 53 (Mean ± 95%CI)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Attention‐control <italic toggle="yes">N</italic> = 51 (Mean ± 95%CI)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="4" valign="top" rowspan="1">Prespecified</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CA125 (U/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">49.84 (15.81,115.49)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16.2 (7.45,25.03)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CRP (mg/L)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.37 (2.86, 5.87)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5.96 (3.09, 8.82)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IGF‐1 (ng/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">90.88 (79.91, 101.84)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">77.7 (68.7, 86.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.07</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Insulin (μU/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13.23 (10.88, 15.57)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16.41 (13.23, 19.58)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Leptin (ng/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30.89 (22.02, 39.77)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.98 (30.12,41.83)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.34</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" valign="top" rowspan="1">Exploratory</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adiponectin (μg/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">
                          <p>17.42 (14.79,20.04)</p>
                        </td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16.93 (14.08, 19.78)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.80</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IL‐6 (pg/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.06 (1.66, 2.46)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.21 (1.73, 2.69)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TNFα (pg/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.06 (0.98, 1.14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.24 (1.10, 1.38)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.03</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VEGF (pg/mL)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">286.77 (226.38,347.16)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">269.70 (204.47,334.94)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.70</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam46187-ntgp-0003">
                    <fn id="cam46187-note-0004">
                      <p><italic toggle="yes">Abbreviations</italic>: CA125; cancer antigen 125; CI, confidence interval; CRP, C‐reactive protein; IGF‐1, insulin‐like growth factor 1; IL‐6, interleukin 6; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="cam46187-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Effect of exercise versus attention‐control on baseline to 6‐month changes in prespecified and exploratory serum biomarkers.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Biomarker</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Exercise intervention<xref rid="cam46187-note-0006" ref-type="table-fn"><sup>a</sup></xref>
<italic toggle="yes">N</italic> = 53</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Attention‐control<xref rid="cam46187-note-0006" ref-type="table-fn"><sup>a</sup></xref>
<italic toggle="yes">N</italic> = 51</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Group difference (intervention vs. control)<xref rid="cam46187-note-0006" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">Prespecified</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">CA125 (U/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.4 (−4.0, 74.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.4 (−4.0, 74.8)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">4.2 (−9.1, 17.5)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">72.8 (−3.9, 149.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">68.6 (−8.5, 146.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">37.4 (−3.6, 78.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">33.2 (−7.9, 74.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">CRP (mg/L)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3 (−3.0, 7.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3 (−3.0, 7.5)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">−0.1 (−2.9, 2.7)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.95</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.9 (−3.6, 7.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.9 (−3.4, 7.3)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−0.4 (−2.6, 1.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−0.3 (−2.6, 2.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">IGF‐1 (ng/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">95.3 (69.6, 121.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">95.3 (69.6, 121.0)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">−14.2 (−26.1, −2.3)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">85.0 (58.3, 112.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">99.2 (72.9, 126.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−10.3 (−18.9, −1.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.9 (−5.3, 13.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">Insulin (μU/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14.6 (6.5, 22.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14.6 (6.5, 22.8)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">−2.0 (−6.5, 2.4)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.37</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16.1 (7.4, 24.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18.1 (9.3, 26.9)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.4 (−1.6, 4.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.5 (0.2, 6.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">Leptin (ng/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.5 (−4.1, 35.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.5 (−4.1, 35.1)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">−8.9 (−16.5, −1.4)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11.1 (−9.0, 31.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20.0 (0.2, 39.8)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−4.4 (−9.9, 1.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.5 (−1.3, 10.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">Exploratory</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">Adiponectin (μg/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.2 (8.2, 22.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.2 (8.2, 22.1)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">−0.4 (−3.2, 2.5)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.80</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14.3 (7.1, 21.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14.7 (7.6, 21.7)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−0.9 (−2.9, 1.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−0.5 (−2.7, 1.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">IL‐6 (pg/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.0 (0.8, 3.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.0 (0.8, 3.1)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.1 (−1.0, 1.0)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.97</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.1 (0.8, 3.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.1 (0.8, 3.4)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.2 (−0.6, 0.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.1 (−0.6, 0.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">TNFα (pg/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.7, 1.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.7, 1.3)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.04 (−0.1, 0.2)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.7, 1.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.7, 1.3)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.0, 0.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.0 (−0.1, 0.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" valign="top" rowspan="1">VEGF (pg/mL)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">287.3 (116.7458.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">287.3 (116.7458.0)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">57.3 (17.5, 97.1)</td>
                        <td rowspan="3" align="char" valign="top" colspan="1">0.005</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">327.2 (155.0,499.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">269.9 (98.6, 441.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">6‐month change</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">39.9 (12.3, 67.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−17.4 (−47.0, 12.3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam46187-ntgp-0004">
                    <fn id="cam46187-note-0005">
                      <p><italic toggle="yes">Abbreviations</italic>: CA125; cancer antigen 125; CI, confidence interval; CRP, C‐reactive protein; IGF‐1, insulin‐like growth factor 1; IL‐6, interleukin 6; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.</p>
                    </fn>
                    <fn id="cam46187-note-0006">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>The baseline, 6‐month and 6‐month change from baseline are least squared means and 95% confidence interval from linear mixed effects model analysis with baseline values, site, recurrence prior to baseline, chemotherapy at baseline, and two stratification factors for randomization (stage and age) held constant.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Of the exploratory biomarker analyses, significant between‐group differences were observed for baseline to 6‐month changes for VEGF (exercise group 39.9 (12.3, 67.6) pg/mL; attention‐control −17.4 (−47.0, 12.3) pg/mL; between group difference <italic toggle="yes">p</italic> = 0.005). No between group differences were observed for adiponectin, IL‐6 or TNF‐α (Table <xref rid="cam46187-tbl-0003" ref-type="table">3</xref>).</p>
                <p>When stratified by recurrence of ovarian cancer during the study, in the group who did not experience a recurrence, the exercise intervention effect for serum leptin was not significant (<italic toggle="yes">p</italic> = 0.40). In contrast, in those who experienced a recurrence the exercise effect on leptin levels was statistically significant with an increase of 30.61 (17.30, 43.93) ng/mL in the attention‐control group compared to decline of −8.21 (−22.46, 6.03) ng/mL in the exercise group, <italic toggle="yes">p</italic> &lt; 0.0001; interaction effect <italic toggle="yes">p</italic> = 0.0008.</p>
              </sec>
              <sec id="cam46187-sec-0019">
                <label>3.5</label>
                <title>Survival analysis</title>
                <p>The baseline characteristics for the full study population (<italic toggle="yes">n</italic> = 144) were balanced between the two study arms (exercise <italic toggle="yes">n</italic> = 74; attention‐control <italic toggle="yes">n</italic> = 70; Table <xref rid="cam46187-tbl-0001" ref-type="table">1</xref>).<xref rid="cam46187-bib-0025" ref-type="bibr"><sup>25</sup></xref> Women randomized to the exercise arm participated in 166 ± 66.1 (mean ± SD) minutes per week of moderate‐intensity exercise and 48 (64.9%) met the exercise goal of at least 150 minutes per week. Those who did not meet the exercise goal of 150 minutes per week (<italic toggle="yes">n</italic> = 26) exercised on average 107 ± 42 minutes per week.</p>
                <p>From study enrollment through December 31, 2018, 50 (34.7%) study participants had died, 24 women (32.4%) in the exercise arm versus 26 women (37.1%) in the attention‐control arm, <italic toggle="yes">p</italic> = 0.91. Malignancy was the underlying cause of death for most women (80.0%). Median follow‐up time was similar in both groups (exercise group: 70.4 (range: 9.9–105.4) months versus attention‐control group: 68.9 (6.6–105.3) months). There was no difference in overall survival between those randomized to the exercise group and those randomized to the attention‐control arm (<italic toggle="yes">p</italic> = 0.99; Figure <xref rid="cam46187-fig-0002" ref-type="fig">2</xref>).</p>
                <fig position="float" fig-type="FIGURE" id="cam46187-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Cumulative incidence of death in the exercise group and attention‐control group.</p>
                  </caption>
                  <graphic xlink:href="CAM4-12-15492-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
                <p>In those with biomarker data available (<italic toggle="yes">n</italic> = 104), lower baseline IL‐6 was associated with improved survival (hazard ratio (HR): 1.33; 95% CI: 1.08–1.64) after adjusting for baseline exercise level, age, stage, recurrence prior to enrollment, and employment status. Baseline (HR:1.001; 95% CI 1.001–1.003; <italic toggle="yes">p</italic> = 0.01), 6‐month (HR: 1.03; 95% CI 1.02–1.05; <italic toggle="yes">p</italic> &lt; 0.0001) and change from baseline to 6‐month (HR: 1.03; 95% CI 1.01–1.05; <italic toggle="yes">p</italic> = 0.0002) CA‐125 were all associated with survival adjusted for age and stage at enrollment. No other biomarkers (baseline, 6‐months, or baseline to 6‐month change for insulin, IL‐6, TNFα, IGF‐1, VEGF CRP) were associated with overall survival (Appendix <xref rid="cam46187-app-0001" ref-type="app">1</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cam46187-sec-0020">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>Our exercise intervention among women with ovarian cancer resulted in changes in two prespecified biomarkers in the exercise group compared to the attention‐control group, a 57.4% reduction in serum leptin and a 14.9% reduction in IGF‐1. No exercise intervention effect was seen for CA‐125, CRP, or insulin. An exercise intervention effect was observed for VEGF with a 20.0% increase in the exercise compared to the attention‐control group, but no effect of exercise was seen for the other exploratory biomarkers, adiponectin, IL‐6, or TNFα. To our knowledge, this is the first intervention study reporting the effects of exercise on cancer‐related circulating biomarkers in women with ovarian cancer.</p>
              <p>Similar to our findings, a recent randomized controlled trial in women with breast cancer, showed a favorable exercise effect on serum IGF‐1.<xref rid="cam46187-bib-0014" ref-type="bibr"><sup>14</sup></xref> In contrast, two meta‐analyses of randomized controlled trials examining the effects of exercise on circulating biomarkers among breast cancer survivors found no significant exercise effect on IGF‐1.<xref rid="cam46187-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cam46187-bib-0030" ref-type="bibr"><sup>30</sup></xref>
</p>
              <p>The relationship of post diagnostic serum IGF‐1 levels and cancer survival has not been well studied. It is thought that IGF‐1 increases cellular growth and may, therefore, promote tumorigenesis.<xref rid="cam46187-bib-0031" ref-type="bibr"><sup>31</sup></xref> In support of this hypothesis, in two large pooled analyses of case–control studies, IGF‐1 levels have been shown to be positively associated with increased risk of breast<xref rid="cam46187-bib-0032" ref-type="bibr"><sup>32</sup></xref> and prostate cancer.<xref rid="cam46187-bib-0033" ref-type="bibr"><sup>33</sup></xref> In contrast, a pooled analysis of 1270 ovarian cancer cases and 2907 matched controls showed lower IGF‐1 concentrations were associated with higher risk of epithelial invasive ovarian cancer.<xref rid="cam46187-bib-0034" ref-type="bibr"><sup>34</sup></xref> Similarly, two of three meta‐analyses of case–control studies reported that low IGF‐1 levels are associated with increased risk of ovarian cancer,<xref rid="cam46187-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="cam46187-bib-0036" ref-type="bibr"><sup>36</sup></xref> with the third meta‐analysis showing no association.<xref rid="cam46187-bib-0037" ref-type="bibr"><sup>37</sup></xref> Further research on the association between IGF‐1 post diagnosis and mortality in ovarian cancer patients is needed.</p>
              <p>Leptin levels are strongly influenced by both physical activity<xref rid="cam46187-bib-0038" ref-type="bibr"><sup>38</sup></xref> and body fat. Similar to our finding of a reduction of leptin in the exercise compared to the attention‐control arm, several meta‐analyses, and systematic reviews of exercise on inflammatory biomarkers in women treated for breast cancer, similarly report a significant reduction in leptin levels in the exercise group compared to the control group.<xref rid="cam46187-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cam46187-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam46187-bib-0018" ref-type="bibr"><sup>18</sup></xref>
</p>
              <p>Evidence suggests that leptin may be involved in the metastatic process<xref rid="cam46187-bib-0039" ref-type="bibr"><sup>39</sup></xref> with higher tissue leptin associated with poorer outcomes in ovarian cancer patients.<xref rid="cam46187-bib-0040" ref-type="bibr"><sup>40</sup></xref> However, evidence on the association between circulating leptin and ovarian cancer risk or prognosis is limited.</p>
              <p>VEGF plays a key role in angiogenesis,<xref rid="cam46187-bib-0041" ref-type="bibr"><sup>41</sup></xref> for example VEGF in skeletal muscle increases as part of the angiogenic response to exercise.<xref rid="cam46187-bib-0042" ref-type="bibr"><sup>42</sup></xref> However, as a key molecule in tumor angiogenesis VEGF has been shown to be associated with tumor growth and adverse tumor outcomes in ovarian cancer,<xref rid="cam46187-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="cam46187-bib-0024" ref-type="bibr"><sup>24</sup></xref> with the anti‐angiogenetic medication bevacizumab, which binds to circulating VEGF, used to treat advanced ovarian cancer.<xref rid="cam46187-bib-0043" ref-type="bibr"><sup>43</sup></xref>
</p>
              <p>Over the course of our 6‐month study, circulating VEGF concentrations increased significantly in those assigned to the exercise intervention group compared to those in the attention‐control group. Our result is in contrast to two independent randomized controlled trials in inactive but health postmenopausal women. In a 12‐month RCT, Brenner et al., reported that there was no difference in circulating VEGF between study arms in which women were randomized to 150 (<italic toggle="yes">n</italic> = 191) versus 300 (<italic toggle="yes">n</italic> = 195) minutes per week of exercise.<xref rid="cam46187-bib-0044" ref-type="bibr"><sup>44</sup></xref> In a 4‐arm RCT comparing low calorie diet (<italic toggle="yes">n</italic> = 118), 225 min/week aerobic exercise (<italic toggle="yes">n</italic> = 117), diet+aerobic exercise (<italic toggle="yes">n</italic> = 117) and control (<italic toggle="yes">n</italic> = 87), Duggan et al. reported no differences in serum VEGF levels over the 12‐month study between women randomized to aerobic exercise versus control.<xref rid="cam46187-bib-0045" ref-type="bibr"><sup>45</sup></xref> Similarly in a small pilot RCT which enrolled men under active surveillance for prostate cancer, no effect of exercise was seen on VEGF levels.<xref rid="cam46187-bib-0046" ref-type="bibr"><sup>46</sup></xref> As our study findings conflict with those of other studies, the effect of exercise on circulating VEGF in ovarian cancer patients warrants further research.</p>
              <p>Unlike a meta‐analysis of women with breast cancer,<xref rid="cam46187-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cam46187-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cam46187-bib-0030" ref-type="bibr"><sup>30</sup></xref> we saw no effect of exercise on circulating insulin. However, similar to a recent meta‐analysis of the effect of exercise on inflammatory markers in breast cancer patients we saw no effect of exercise on IL‐6 or TNF‐alpha.<xref rid="cam46187-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cam46187-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cam46187-bib-0017" ref-type="bibr"><sup>17</sup></xref>
</p>
              <p>To the best of our knowledge, no randomized trials have been reported examining the effect of exercise on overall survival in women with ovarian cancer. In our exploratory analysis, we found no benefit on overall survival of our 6‐month exercise intervention. This contrasts with several observational studies that have reported exercise post diagnosis associated with reduced mortality of ovarian cancer.<xref rid="cam46187-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cam46187-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cam46187-bib-0008" ref-type="bibr"><sup>8</sup></xref> For example, exercise 1–4 years after diagnosis was found to be associated with a 33% lower mortality risk in the combined Nurses' Health study (NHS and NHSII) cohort studies.<xref rid="cam46187-bib-0006" ref-type="bibr"><sup>6</sup></xref>
</p>
              <p>As changes in cancer‐related biomarkers occurred as a result of the 6‐month exercise intervention, future research may be warranted to investigate the effect of exercise on mortality in women soon after diagnosis, as our study population was enrolled after completing initial treatment, on an average of 1.7 years post‐diagnosis, or investigate an exercise intervention of longer duration.</p>
              <p>Study strengths included a 6‐month study duration, randomized design, and the population‐based recruitment approach. The external validity of our findings was strengthened by the limited study exclusion criteria which resulted in recruitment of a broad sample of ovarian cancer survivors. However, it should be noted that the generalizability of our results may be affected by the limited racial diversity in our study population. Additionally, the home‐based, telephone‐delivered exercise program allows for straightforward implementation into a clinic‐ or community‐based setting and is cost‐effective. Lastly, adherence to the exercise intervention was excellent.</p>
              <p>Our study is not without limitations. First, our study involved the use of self‐reported physical activity; however, the prospective study design, daily exercise recording, and weekly phone calls with the exercise trainer minimized potential recall bias. In addition, the population had variability in disease stage and clinical characteristics at enrollment with a substantial number of women experiencing recurrent ovarian cancer during the 6‐month study and the effect of this disease burden on the biomarkers assessed is unclear. Notably, the effect of exercise on leptin was only evident in those women who had a recurrence during the study, suggesting a differing effect of exercise on those who had a recurrence versus women who remained disease free. However, this finding should be interpreted with caution as the recurrence status of some women could not be determined. As a subset of participants were included in the biomarker analysis and survival was an exploratory outcome all results are exploratory and thus should be interpreted cautiously.</p>
              <p>In summary, we found that a 6‐month home‐based exercise intervention in women with ovarian cancer resulted in a reduction in leptin and IGF‐1 levels which may have a beneficial effect on cancer‐related outcomes, but also an increase in circulating levels of VEGF. We did not observe any effect of the exercise intervention on survival. Future studies examining the impact of modifiable lifestyle behaviors on ovarian cancer outcomes are needed. The LIVES study is examining the impact of a diet and exercise intervention on ovarian cancer survival.<xref rid="cam46187-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="cam46187-bib-0048" ref-type="bibr"><sup>48</sup></xref> Their findings in addition to ours and those from other studies of lifestyle behaviors and cancer outcomes will provide important information for developing personalized treatment strategies and fostering shared decision making for cancer prevention and control.</p>
            </sec>
            <sec id="cam46187-sec-0027">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Brenda Cartmel:</bold> Data curation (equal); project administration (equal); supervision (equal); writing – original draft (lead). <bold>Fang‐yong Li:</bold> Data curation (equal); formal analysis (lead); writing – review and editing (equal). <bold>Yang Zhou:</bold> Data curation (equal); writing – review and editing (equal). <bold>Linda Gottlieb:</bold> Investigation (equal); writing – review and editing (equal). <bold>Lingeng Lu:</bold> Investigation (equal); writing – review and editing (equal). <bold>Reed Mszar:</bold> Writing – original draft (supporting). <bold>Maura Harrigan:</bold> Investigation (equal); writing – review and editing (equal). <bold>Jennifer A. Ligibel:</bold> Investigation (equal); project administration (equal); supervision (equal); writing – review and editing (equal). <bold>Radhika Gogoi:</bold> Investigation (equal); project administration (equal); supervision (equal); writing – review and editing (equal). <bold>Peter E. Schwartz:</bold> Conceptualization (supporting); resources (equal); writing – review and editing (equal). <bold>Harvey A. Risch:</bold> Conceptualization (supporting); writing – review and editing (equal). <bold>Melinda L. Irwin:</bold> Conceptualization (lead); funding acquisition (lead); project administration (equal); supervision (equal); writing – review and editing (lead).</p>
            </sec>
            <sec sec-type="COI-statement" id="cam46187-sec-0022">
              <title>CONFLICT OF INTEREST STATEMENT</title>
              <p>The authors declare no conflicts of interest.</p>
            </sec>
            <sec id="cam46187-sec-0021">
              <title>ETHICAL APPROVAL STATEMENT</title>
              <p>The study was approved by the Yale Human Investigation and the Connecticut Department of Public Health Committees, Geisinger Health Systems IRB, Dana‐Farber/Harvard Cancer Center Institutional Review Board (IRB), and all 21 Connecticut hospital IRBs. All participants gave written informed consent.</p>
            </sec>
          </body>
          <back>
            <ack id="cam46187-sec-0023">
              <title>ACKNOWLEDGMENTS</title>
              <p>We thank the following Connecticut hospitals: Charlotte Hungerford Hospital, Bridgeport Hospital, Danbury Hospital, Hartford Hospital, Middlesex Hospital, New Britain General Hospital, Bradley Memorial Hospital, Yale/New Haven Hospital, St. Francis Hospital and Medical Center, St. Mary's Hospital, Hospital of St. Raphael, St. Vincent's Medical Center, Stamford Hospital, William W. Backus Hospital, Windham Hospital, Eastern Connecticut Health Network, Griffin Hospital, Bristol Hospital, Johnson Memorial Hospital, Day Kimball Hospital, Greenwich Hospital, Lawrence and Memorial Hospital, Milford Hospital, New Milford Hospital, Norwalk Hospital, Sharon Hospital, and Waterbury Hospital; Rajni Mehta, the Rapid Case Ascertainment Shared Resource of the Yale Cancer Center Director; and all the study participants and physicians. The authors assume full responsibility for analyses and interpretation of the data collected from the Connecticut Tumor Registry. Certain data used in this study were obtained from the Connecticut Tumor Registry located in the Connecticut Department of Public Health. This study was supported by the National Cancer Institute at the National Institutes of Health (NCI 5R01CA138556, P30 CA016359); and by the National Center for Advancing Translational Science at the National Institutes of Health (UL1TR000142).</p>
            </ack>
            <sec sec-type="data-availability" id="cam46187-sec-0025">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data underlying this article will be shared on reasonable request, after data use agreement, to the corresponding author.</p>
            </sec>
            <ref-list content-type="cited-references" id="cam46187-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cam46187-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0001"><string-name><surname>Torre</surname><given-names>LA</given-names></string-name>, <string-name><surname>Trabert</surname><given-names>B</given-names></string-name>, <string-name><surname>DeSantis</surname><given-names>CE</given-names></string-name>, et al. <article-title>Ovarian cancer statistics, 2018</article-title>. <source>CA Cancer J Clin</source>. <year>2018</year>;<volume>68</volume>:<fpage>284</fpage>‐<lpage>296</lpage>.<pub-id pub-id-type="pmid">29809280</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0002"><string-name><surname>Cormie</surname><given-names>P</given-names></string-name>, <string-name><surname>Zopf</surname><given-names>EM</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Schmitz</surname><given-names>KH</given-names></string-name>. <article-title>The impact of exercise on cancer mortality, recurrence, and treatment‐related adverse effects</article-title>. <source>Epidemiol Rev</source>. <year>2017</year>;<volume>39</volume>:<fpage>71</fpage>‐<lpage>92</lpage>.<pub-id pub-id-type="pmid">28453622</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0003"><string-name><surname>Ballard‐Barbash</surname><given-names>R</given-names></string-name>, <string-name><surname>Friedenreich</surname><given-names>CM</given-names></string-name>, <string-name><surname>Courneya</surname><given-names>KS</given-names></string-name>, <string-name><surname>Siddiqi</surname><given-names>SM</given-names></string-name>, <string-name><surname>McTiernan</surname><given-names>A</given-names></string-name>, <string-name><surname>Alfano</surname><given-names>CM</given-names></string-name>. <article-title>Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review</article-title>. <source>J Natl Cancer Inst</source>. <year>2012</year>;<volume>104</volume>:<fpage>815</fpage>‐<lpage>840</lpage>.<pub-id pub-id-type="pmid">22570317</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0004"><string-name><surname>Schmid</surname><given-names>D</given-names></string-name>, <string-name><surname>Leitzmann</surname><given-names>MF</given-names></string-name>. <article-title>Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta‐analysis</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>:<fpage>1293</fpage>‐<lpage>1311</lpage>.<pub-id pub-id-type="pmid">24644304</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0005"><string-name><surname>Patel</surname><given-names>AV</given-names></string-name>, <string-name><surname>Friedenreich</surname><given-names>CM</given-names></string-name>, <string-name><surname>Moore</surname><given-names>SC</given-names></string-name>, et al. <article-title>American College of Sports Medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control</article-title>. <source>Med Sci Sports Exerc</source>. <year>2019</year>;<volume>51</volume>:<fpage>2391</fpage>‐<lpage>2402</lpage>.<pub-id pub-id-type="pmid">31626056</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0006"><string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name><surname>Townsend</surname><given-names>MK</given-names></string-name>, <string-name><surname>Eliassen</surname><given-names>AH</given-names></string-name>, et al. <article-title>Prediagnosis and postdiagnosis leisure time physical activity and survival following diagnosis with ovarian cancer</article-title>. <source>Int J Cancer</source>. <year>2021</year>;<volume>149</volume>:<fpage>1067</fpage>‐<lpage>1075</lpage>.<pub-id pub-id-type="pmid">33963766</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0007"><string-name><surname>Abbott</surname><given-names>SE</given-names></string-name>, <string-name><surname>Camacho</surname><given-names>F</given-names></string-name>, <string-name><surname>Peres</surname><given-names>LC</given-names></string-name>, et al. <article-title>Recreational physical activity and survival in African‐American women with ovarian cancer</article-title>. <source>Cancer Causes Control</source>. <year>2018</year>;<volume>29</volume>:<fpage>77</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">29188593</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0008"><string-name><surname>Cannioto</surname><given-names>RA</given-names></string-name>, <string-name><surname>Dighe</surname><given-names>S</given-names></string-name>, <string-name><surname>Mahoney</surname><given-names>MC</given-names></string-name>, et al. <article-title>Habitual recreational physical activity is associated with significantly improved survival in cancer patients: evidence from the Roswell Park data Bank and BioRepository</article-title>. <source>Cancer Causes Control</source>. <year>2019</year>;<volume>30</volume>:<fpage>1</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">30488344</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0009"><string-name><surname>Poole</surname><given-names>EM</given-names></string-name>, <string-name><surname>Konstantinopoulos</surname><given-names>PA</given-names></string-name>, <string-name><surname>Terry</surname><given-names>KL</given-names></string-name>. <article-title>Prognostic implications of reproductive and lifestyle factors in ovarian cancer</article-title>. <source>Gynecol Oncol</source>. <year>2016</year>;<volume>142</volume>:<fpage>574</fpage>‐<lpage>587</lpage>.<pub-id pub-id-type="pmid">27189457</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0010"><string-name><surname>Friedenreich</surname><given-names>CM</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>E</given-names></string-name>, <string-name><surname>Neilson</surname><given-names>HK</given-names></string-name>, <string-name><surname>Brenner</surname><given-names>DR</given-names></string-name>. <article-title>Epidemiology and biology of physical activity and cancer recurrence</article-title>. <source>J Mol Med (Berl)</source>. <year>2017</year>;<volume>95</volume>:<fpage>1029</fpage>‐<lpage>1041</lpage>.<pub-id pub-id-type="pmid">28620703</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0011"><string-name><surname>Brown</surname><given-names>JC</given-names></string-name>, <string-name><surname>Gilmore</surname><given-names>LA</given-names></string-name>. <article-title>Physical activity reduces the risk of recurrence and mortality in cancer patients</article-title>. <source>Exerc Sport Sci Rev</source>. <year>2020</year>;<volume>48</volume>:<fpage>67</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">31913187</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0012"><string-name><surname>Hong</surname><given-names>BS</given-names></string-name>, <string-name><surname>Lee</surname><given-names>KP</given-names></string-name>. <article-title>A systematic review of the biological mechanisms linking physical activity and breast cancer</article-title>. <source>Phys Act Nutr</source>. <year>2020</year>;<volume>24</volume>:<fpage>25</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">33108715</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0013"><string-name><surname>Abbasi</surname><given-names>F</given-names></string-name>, <string-name><surname>Pourjalali</surname><given-names>H</given-names></string-name>, <string-name><surname>do Nascimento</surname><given-names>IJB</given-names></string-name>, et al. <article-title>The effects of exercise training on inflammatory biomarkers in patients with breast cancer: a systematic review and meta‐analysis</article-title>. <source>Cytokine</source>. <year>2022</year>;<volume>149</volume>:<elocation-id>155712</elocation-id>.<pub-id pub-id-type="pmid">34644675</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0014"><string-name><surname>Dieli‐Conwright</surname><given-names>CM</given-names></string-name>, <string-name><surname>Courneya</surname><given-names>KS</given-names></string-name>, <string-name><surname>Demark‐Wahnefried</surname><given-names>W</given-names></string-name>, et al. <article-title>Effects of aerobic and resistance exercise on metabolic syndrome, Sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial</article-title>. <source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>:<fpage>875</fpage>‐<lpage>883</lpage>.<pub-id pub-id-type="pmid">29356607</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0015"><string-name><surname>Hartman</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>LS</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>SH</given-names></string-name>, et al. <article-title>Mediators of a physical activity intervention on cognition in breast cancer survivors: evidence from a randomized controlled trial</article-title>. <source>JMIR Cancer</source>. <year>2019</year>;<volume>5</volume>:<elocation-id>e13150</elocation-id>.<pub-id pub-id-type="pmid">31605514</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0016"><string-name><surname>Zhu</surname><given-names>G</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sun</surname><given-names>F</given-names></string-name>. <article-title>Effects of exercise intervention in breast cancer survivors: a meta‐analysis of 33 randomized controlled trails</article-title>. <source>Onco Targets Ther</source>. <year>2016</year>;<volume>9</volume>:<fpage>2153</fpage>‐<lpage>2168</lpage>.<pub-id pub-id-type="pmid">27110131</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0017"><string-name><surname>Bruinsma</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Dyer</surname><given-names>AM</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Schmitz</surname><given-names>KH</given-names></string-name>, <string-name><surname>Sturgeon</surname><given-names>KM</given-names></string-name>. <article-title>Effects of diet and exercise‐induced weight loss on biomarkers of inflammation in breast cancer survivors: a systematic review and meta‐analysis</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2021</year>;<volume>30</volume>:<fpage>1048</fpage>‐<lpage>1062</lpage>.<pub-id pub-id-type="pmid">33737299</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0018"><string-name><surname>Invernizzi</surname><given-names>M</given-names></string-name>, <string-name><surname>Lippi</surname><given-names>L</given-names></string-name>, <string-name><surname>Folli</surname><given-names>A</given-names></string-name>, et al. <article-title>Integrating molecular biomarkers in breast cancer rehabilitation. What is the current evidence? A systematic review of randomized controlled trials</article-title>. <source>Front Mol Biosci</source>. <year>2022</year>;<volume>9</volume>:<elocation-id>930361</elocation-id>.<pub-id pub-id-type="pmid">36158576</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0019"><string-name><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>. <article-title>Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer</article-title>. <source>Biochim Biophys Acta Rev Cancer</source>. <year>2021</year>;<volume>1875</volume>:<elocation-id>188503</elocation-id>.<pub-id pub-id-type="pmid">33421585</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0020"><string-name><surname>Booth</surname><given-names>A</given-names></string-name>, <string-name><surname>Magnuson</surname><given-names>A</given-names></string-name>, <string-name><surname>Fouts</surname><given-names>J</given-names></string-name>, <string-name><surname>Foster</surname><given-names>M</given-names></string-name>. <article-title>Adipose tissue, obesity and adipokines: role in cancer promotion</article-title>. <source>Horm Mol Biol Clin Investig</source>. <year>2015</year>;<volume>21</volume>:<fpage>57</fpage>‐<lpage>74</lpage>.</mixed-citation>
              </ref>
              <ref id="cam46187-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0021"><string-name><surname>McTiernan</surname><given-names>A</given-names></string-name>. <article-title>Mechanisms linking physical activity with cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2008</year>;<volume>8</volume>:<fpage>205</fpage>‐<lpage>211</lpage>.<pub-id pub-id-type="pmid">18235448</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0022"><string-name><surname>Masoumi Moghaddam</surname><given-names>S</given-names></string-name>, <string-name><surname>Amini</surname><given-names>A</given-names></string-name>, <string-name><surname>Morris</surname><given-names>DL</given-names></string-name>, <string-name><surname>Pourgholami</surname><given-names>MH</given-names></string-name>. <article-title>Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer</article-title>. <source>Cancer Metastasis Rev</source>. <year>2012</year>;<volume>31</volume>:<fpage>143</fpage>‐<lpage>162</lpage>.<pub-id pub-id-type="pmid">22101807</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0023"><string-name><surname>Fahmi</surname><given-names>MN</given-names></string-name>, <string-name><surname>Pradjatmo</surname><given-names>H</given-names></string-name>, <string-name><surname>Astuti</surname><given-names>I</given-names></string-name>, <string-name><surname>Nindrea</surname><given-names>RD</given-names></string-name>. <article-title>Cytokines as prognostic biomarkers of epithelial ovarian cancer (EOC): a systematic review and meta‐analysis</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2021</year>;<volume>22</volume>:<fpage>315</fpage>‐<lpage>323</lpage>.<pub-id pub-id-type="pmid">33639643</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0024"><string-name><surname>Trifanescu</surname><given-names>OG</given-names></string-name>, <string-name><surname>Gales</surname><given-names>LN</given-names></string-name>, <string-name><surname>Tanase</surname><given-names>BC</given-names></string-name>, et al. <article-title>Prognostic role of vascular endothelial growth factor and correlation with oxidative stress markers in locally advanced and metastatic ovarian cancer patients</article-title>. <source>Diagnostics (Basel)</source>. <year>2023</year>;<volume>13</volume>:<fpage>13</fpage>.</mixed-citation>
              </ref>
              <ref id="cam46187-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0025"><string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cartmel</surname><given-names>B</given-names></string-name>, <string-name><surname>Gottlieb</surname><given-names>L</given-names></string-name>, et al. <article-title>Randomized trial of exercise on quality of life in women with ovarian cancer: Women's activity and lifestyle study in Connecticut (WALC)</article-title>. <source>J Natl Cancer Inst</source>. <year>2017</year>;<volume>109</volume>:<fpage>djx072</fpage>.<pub-id pub-id-type="pmid">30053074</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0026"><string-name><surname>Pettee Gabriel</surname><given-names>K</given-names></string-name>, <string-name><surname>McClain</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Schmid</surname><given-names>KK</given-names></string-name>, <string-name><surname>Storti</surname><given-names>KL</given-names></string-name>, <string-name><surname>Ainsworth</surname><given-names>BE</given-names></string-name>. <article-title>Reliability and convergent validity of the past‐week modifiable activity questionnaire</article-title>. <source>Public Health Nutr</source>. <year>2011</year>;<volume>14</volume>:<fpage>435</fpage>‐<lpage>442</lpage>.<pub-id pub-id-type="pmid">20843404</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0027"><string-name><surname>Schmitz</surname><given-names>KH</given-names></string-name>, <string-name><surname>Courneya</surname><given-names>KS</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>C</given-names></string-name>, et al. <article-title>American College of Sports Medicine roundtable on exercise guidelines for cancer survivors</article-title>. <source>Med Sci Sports Exerc</source>. <year>2010</year>;<volume>42</volume>:<fpage>1409</fpage>‐<lpage>1426</lpage>.<pub-id pub-id-type="pmid">20559064</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="book" id="cam46187-cit-0028"><string-name><surname>Fitzmaurice</surname><given-names>GM</given-names></string-name>, <string-name><surname>Laird</surname><given-names>NM</given-names></string-name>, <string-name><surname>Ware</surname><given-names>JH</given-names></string-name>. <source>Applied Longitudinal Analysis</source>. <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="cam46187-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="miscellaneous" id="cam46187-cit-0029"><string-name><surname>Allison</surname><given-names>PD</given-names></string-name>. <article-title>Handling missing data by maximum likelihood</article-title>. SAS Global Forum [serial online] <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="cam46187-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0030"><string-name><surname>Kang</surname><given-names>DW</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Suh</surname><given-names>SH</given-names></string-name>, <string-name><surname>Ligibel</surname><given-names>J</given-names></string-name>, <string-name><surname>Courneya</surname><given-names>KS</given-names></string-name>, <string-name><surname>Jeon</surname><given-names>JY</given-names></string-name>. <article-title>Effects of exercise on insulin, IGF Axis, Adipocytokines, and inflammatory markers in breast cancer survivors: a systematic review and meta‐analysis</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2017</year>;<volume>26</volume>:<fpage>355</fpage>‐<lpage>365</lpage>.<pub-id pub-id-type="pmid">27742668</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0031"><string-name><surname>Schmidt</surname><given-names>S</given-names></string-name>, <string-name><surname>Monk</surname><given-names>JM</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>LE</given-names></string-name>, <string-name><surname>Mourtzakis</surname><given-names>M</given-names></string-name>. <article-title>The integrative role of leptin, oestrogen and the insulin family in obesity‐associated breast cancer: potential effects of exercise</article-title>. <source>Obes Rev</source>. <year>2015</year>;<volume>16</volume>:<fpage>473</fpage>‐<lpage>487</lpage>.<pub-id pub-id-type="pmid">25875578</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0032"><collab collab-type="authors">Endogenous Hormones Breast Cancer Collaborative Group</collab>
, <string-name><surname>Key</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Appleby</surname><given-names>PN</given-names></string-name>, <string-name><surname>Reeves</surname><given-names>GK</given-names></string-name>, <string-name><surname>Roddam</surname><given-names>AW</given-names></string-name>. <article-title>Insulin‐like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies</article-title>. <source>Lancet Oncol</source>. <year>2010</year>;<volume>11</volume>:<fpage>530</fpage>‐<lpage>542</lpage>.<pub-id pub-id-type="pmid">20472501</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0033"><string-name><surname>Travis</surname><given-names>RC</given-names></string-name>, <string-name><surname>Appleby</surname><given-names>PN</given-names></string-name>, <string-name><surname>Martin</surname><given-names>RM</given-names></string-name>, et al. <article-title>A meta‐analysis of individual participant data reveals an association between circulating levels of IGF‐I and prostate cancer risk</article-title>. <source>Cancer Res</source>. <year>2016</year>;<volume>76</volume>:<fpage>2288</fpage>‐<lpage>2300</lpage>.<pub-id pub-id-type="pmid">26921328</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0034"><string-name><surname>Ose</surname><given-names>J</given-names></string-name>, <string-name><surname>Schock</surname><given-names>H</given-names></string-name>, <string-name><surname>Poole</surname><given-names>EM</given-names></string-name>, et al. <article-title>Pre‐diagnosis insulin‐like growth factor‐I and risk of epithelial invasive ovarian cancer by histological subtypes: a collaborative re‐analysis from the ovarian cancer cohort consortium</article-title>. <source>Cancer Causes Control</source>. <year>2017</year>;<volume>28</volume>:<fpage>429</fpage>‐<lpage>435</lpage>.<pub-id pub-id-type="pmid">28205047</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0035"><string-name><surname>Gianuzzi</surname><given-names>X</given-names></string-name>, <string-name><surname>Palma‐Ardiles</surname><given-names>G</given-names></string-name>, <string-name><surname>Hernandez‐Fernandez</surname><given-names>W</given-names></string-name>, <string-name><surname>Pasupuleti</surname><given-names>V</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AV</given-names></string-name>, <string-name><surname>Perez‐Lopez</surname><given-names>FR</given-names></string-name>. <article-title>Insulin growth factor (IGF) 1, IGF‐binding proteins and ovarian cancer risk: a systematic review and meta‐analysis</article-title>. <source>Maturitas</source>. <year>2016</year>;<volume>94</volume>:<fpage>22</fpage>‐<lpage>29</lpage>.<pub-id pub-id-type="pmid">27823741</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0036"><string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, et al. <article-title>Circulating insulin‐like growth Factor‐1 level and ovarian cancer risk</article-title>. <source>Cell Physiol Biochem</source>. <year>2016</year>;<volume>38</volume>:<fpage>589</fpage>‐<lpage>597</lpage>.<pub-id pub-id-type="pmid">26845340</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0037"><string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Bian</surname><given-names>CE</given-names></string-name>, <string-name><surname>Peng</surname><given-names>H</given-names></string-name>, <string-name><surname>He</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>. <article-title>Association of circulating insulin‐like growth factor 1 and insulin‐like growth factor binding protein 3 with the risk of ovarian cancer: a systematic review and meta‐analysis</article-title>. <source>Mol Clin Oncol</source>. <year>2015</year>;<volume>3</volume>:<fpage>623</fpage>‐<lpage>628</lpage>.<pub-id pub-id-type="pmid">26137278</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0038"><string-name><surname>Fedewa</surname><given-names>MV</given-names></string-name>, <string-name><surname>Hathaway</surname><given-names>ED</given-names></string-name>, <string-name><surname>Ward‐Ritacco</surname><given-names>CL</given-names></string-name>, <string-name><surname>Williams</surname><given-names>TD</given-names></string-name>, <string-name><surname>Dobbs</surname><given-names>WC</given-names></string-name>. <article-title>The effect of chronic exercise training on leptin: a systematic review and meta‐analysis of randomized controlled trials</article-title>. <source>Sports Med</source>. <year>2018</year>;<volume>48</volume>:<fpage>1437</fpage>‐<lpage>1450</lpage>.<pub-id pub-id-type="pmid">29582381</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0039"><string-name><surname>Kato</surname><given-names>S</given-names></string-name>, <string-name><surname>Abarzua‐Catalan</surname><given-names>L</given-names></string-name>, <string-name><surname>Trigo</surname><given-names>C</given-names></string-name>, et al. <article-title>Leptin stimulates migration and invasion and maintains cancer stem‐like properties in ovarian cancer cells: an explanation for poor outcomes in obese women</article-title>. <source>Oncotarget</source>. <year>2015</year>;<volume>6</volume>:<fpage>21100</fpage>‐<lpage>21119</lpage>.<pub-id pub-id-type="pmid">26053184</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0040"><string-name><surname>Uddin</surname><given-names>S</given-names></string-name>, <string-name><surname>Bu</surname><given-names>R</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>M</given-names></string-name>, et al. <article-title>Overexpression of leptin receptor predicts an unfavorable outcome in middle eastern ovarian cancer</article-title>. <source>Mol Cancer</source>. <year>2009</year>;<volume>8</volume>:<fpage>74</fpage>.<pub-id pub-id-type="pmid">19765303</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0041"><string-name><surname>Ferrara</surname><given-names>N</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>HP</given-names></string-name>. <article-title>The role of vascular endothelial growth factor in angiogenesis</article-title>. <source>Acta Haematol</source>. <year>2001</year>;<volume>106</volume>:<fpage>148</fpage>‐<lpage>156</lpage>.<pub-id pub-id-type="pmid">11815711</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0042"><string-name><surname>Wagner</surname><given-names>PD</given-names></string-name>. <article-title>The critical role of VEGF in skeletal muscle angiogenesis and blood flow</article-title>. <source>Biochem Soc Trans</source>. <year>2011</year>;<volume>39</volume>:<fpage>1556</fpage>‐<lpage>1559</lpage>.<pub-id pub-id-type="pmid">22103486</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0043"><string-name><surname>Mao</surname><given-names>CL</given-names></string-name>, <string-name><surname>Seow</surname><given-names>KM</given-names></string-name>, <string-name><surname>Chen</surname><given-names>KH</given-names></string-name>. <article-title>The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>:<fpage>23</fpage>.</mixed-citation>
              </ref>
              <ref id="cam46187-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0044"><string-name><surname>Brenner</surname><given-names>DR</given-names></string-name>, <string-name><surname>Ruan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Adams</surname><given-names>SC</given-names></string-name>, <string-name><surname>Courneya</surname><given-names>KS</given-names></string-name>, <string-name><surname>Friedenreich</surname><given-names>CM</given-names></string-name>. <article-title>The impact of exercise on growth factors (VEGF and FGF2): results from a 12‐month randomized intervention trial</article-title>. <source>Eur Rev Aging Phys Act</source>. <year>2019</year>;<volume>16</volume>:<fpage>8</fpage>.<pub-id pub-id-type="pmid">31285780</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0045"><string-name><surname>Duggan</surname><given-names>C</given-names></string-name>, <string-name><surname>Tapsoba Jde</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>CY</given-names></string-name>, <string-name><surname>McTiernan</surname><given-names>A</given-names></string-name>. <article-title>Dietary weight loss and exercise effects on serum biomarkers of angiogenesis in overweight postmenopausal women: a randomized controlled trial</article-title>. <source>Cancer Res</source>. <year>2016</year>;<volume>76</volume>:<fpage>4226</fpage>‐<lpage>4235</lpage>.<pub-id pub-id-type="pmid">27417562</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0046"><string-name><surname>Moon</surname><given-names>C</given-names></string-name>, <string-name><surname>Gallegos</surname><given-names>AM</given-names></string-name>, <string-name><surname>Sheikh</surname><given-names>B</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>P</given-names></string-name>, <string-name><surname>Liss</surname><given-names>M</given-names></string-name>, <string-name><surname>Patel</surname><given-names>DI</given-names></string-name>. <article-title>Pilot study on the impact of a home‐based exercise program on inflammatory cytokines and quality of life in men with prostate cancer under active surveillance</article-title>. <source>Cancer Control</source>. <year>2022</year>;<volume>29</volume>:<elocation-id>107327482211309</elocation-id>.</mixed-citation>
              </ref>
              <ref id="cam46187-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0047"><string-name><surname>Thomson</surname><given-names>CA</given-names></string-name>, <string-name><surname>Crane</surname><given-names>TE</given-names></string-name>, <string-name><surname>Miller</surname><given-names>A</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>DO</given-names></string-name>, <string-name><surname>Basen‐Engquist</surname><given-names>K</given-names></string-name>, <string-name><surname>Alberts</surname><given-names>DS</given-names></string-name>. <article-title>A randomized trial of diet and physical activity in women treated for stage II‐IV ovarian cancer: rationale and design of the lifestyle intervention for ovarian cancer enhanced survival (LIVES): an NRG oncology/gynecologic oncology group (GOG‐225) study</article-title>. <source>Contemp Clin Trials</source>. <year>2016</year>;<volume>49</volume>:<fpage>181</fpage>‐<lpage>189</lpage>.<pub-id pub-id-type="pmid">27394382</pub-id></mixed-citation>
              </ref>
              <ref id="cam46187-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="cam46187-cit-0048"><string-name><surname>Thomson</surname><given-names>CA</given-names></string-name>, <string-name><surname>Crane</surname><given-names>TE</given-names></string-name>, <string-name><surname>Miller</surname><given-names>A</given-names></string-name>, et al. <article-title>Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors</article-title>. <source>Gynecol Oncol</source>. <year>2023</year>;<volume>170</volume>:<fpage>11</fpage>‐<lpage>18</lpage>.<pub-id pub-id-type="pmid">36608382</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <app-group>
              <app id="cam46187-app-0001" content-type="APPENDIX">
                <label>APPENDIX 1</label>
                <title>Association between biomarkers as baseline, 6 months and 6‐month change from baseline and survival outcomes</title>
                <p>
                  <table-wrap position="anchor" id="jats-table-wrap-1">
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="char" char="(" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="(" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="(" span="1"/>
                      <col align="char" char="." span="1"/>
                      <thead valign="bottom">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Baseline</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">6 months</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">6‐month change from baseline</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left" colspan="7" valign="top" rowspan="1">Prespecified</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CA 125 (U/mL), unit = 5</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.01 (1.005, 1.02)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.0003</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.14 (1.08, 1.20)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.13 (1.07, 1.19)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CRP (mg/L)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.01 (0.98, 1.04)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.48</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.04 (0.99, 1.09)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.10</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.02 (0.96, 1.07)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.55</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IGF‐1 (ng/mL)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.00 (0.99, 1.01)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.75</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.98, 1.01)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.98, 1.00)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.16</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Insulin (μU/mL)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.96, 1.02)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.59</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.95, 1.02)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.45</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.98 (0.93, 1.03)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.42</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Leptin (ng/mL)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.98, 1.01)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.23</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.97, 1.01)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.36</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.00 (0.98, 1.02)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.76</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="7" valign="top" rowspan="1">Exploratory</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adiponectin (μg/mL)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.01 (0.98, 1.05)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.47</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.03 (0.98, 1.07)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.28</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.00 (0.95, 1.06)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.93</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IL‐6 (pg/mL)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.33 (1.11, 1.59)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.002</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.05 (0.94, 1.17)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.41</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.02 (0.90, 1.16)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.70</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TNFα (pg/mL)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.62 (0.24, 1.59)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.99 (0.28, 3.46)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.98</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.41 (0.42, 4.68)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.58</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VEGF(pg/mL), unit = 5</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.00 (0.99, 1.004)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.00 (0.99, 1.01)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.45</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">1.01 (0.99, 1.03)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot id="cam46187-ntgp-0005">
                      <fn id="cam46187-note-0007">
                        <p><italic toggle="yes">Abbreviations</italic>: CA125; cancer antigen 125; CI, confidence interval; CRP, C‐reactive protein; HR, hazard ratio; IGF‐1, insulin‐like growth factor 1; IL‐6, interleukin 6; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </p>
              </app>
            </app-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
